CBAY News and Press, CymaBay Therapeutics Inc. From 07/23/20

Clinical hold lifted on seladelpar INDs in NASH, PBC and PSC  Re-initiating clinical development focusing first on Phase 3 for PBC NEWARK, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on...

There is no guarantee that the FDA will lift the clinical hold on the development of Seladelpar. - CymaBay May 11, 2020 - 10-Q Introduction CymaBay Therapeutics ( CBAY ) is a clinical-stage biopharmaceutical company with a 3-product pipeline specializing primarily in the development of t...

CymaBay Posts Positive Seladelpar Data for Bile Duct Disorder CymaBay Therapeutics ( CBAY ) reported upbeat data for its open label Phase 2 study of seladelpar for treating patients suffering from primary biliary cholangitis. Seladelpar is a potent and selective peroxisome proliferator-a...

Fresh off positive results from a mid-stage study evaluating its lead drug in nonalcoholic steatohepatitis (NASH), French biotech Inventiva S.A. ( IVA ) has filed a preliminary prospectus for a $90M IPO. More news on: Genfit SA, CymaBay Therapeutics, Inc., Inventiva S.A., Healthcare ...

CymaBay Therapeutics ( CBAY +7.1% ) perks up, albeit on below-average volume, on the heels of new data from a previously completed open-label Phase 2 clinical trial evaluating seladelpar in patients with primary biliary cholangitis  (PBC), an autoimmune disorder characterized ...

Data from previously completed open-label phase 2 study supports potential for seladelpar to improve pruritus (itching) in patients with PBC Improvements in other quality-of-life parameters also observed NEWARK, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (...

Introduction In March, I wrote an article about Genfit (NASDAQ: GNFT ) and the potential of its lead drug candidate Elafibranor in NASH. In my analysis, I underlined the huge upward potential but also underpinned the binary characteristic of the investment case. My recommendation was to ...

French biopharma Inventiva ( OTCPK:IVEVF ) has emerged as a new player in the pursuit of a treatment for nonalcoholic steatohepatitis (NASH). More news on: Inventiva S.A., Genfit SA, CymaBay Therapeutics, Inc., Healthcare stocks news, Read more ...

Shares of CymaBay Therapeutics (NASDAQ: CBAY) jumped 109% last month, according to data from S&P Global Market Intelligence . The stock popped when the company reported first-quarter 2020 operating results, which were headlined by an important update on the company's lead drug candidate...

NEWARK, Calif., June 05, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY),  a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that, due to public health and safety...